Insider Selling: DBV Technologies (NASDAQ:DBVT) Major Shareholder Sells 2,076,990 Shares of Stock

DBV Technologies S.A. (NASDAQ:DBVT) major shareholder Bpifrance Epic sold 2,076,990 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $4.85, for a total transaction of $10,073,401.50. Following the completion of the transaction, the insider owned 8,595,472 shares in the company, valued at $41,688,039.20. The trade was a 19.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Bpifrance Epic also recently made the following trade(s):

• On Thursday, December 18th, Bpifrance Epic sold 1,292,103 shares of DBV Technologies stock. The stock was sold at an average price of $4.19, for a total transaction of $5,413,911.57.

DBV Technologies Stock Performance

Shares of NASDAQ DBVT traded up $1.24 during trading hours on Friday, hitting $22.76. The company’s stock had a trading volume of 431,282 shares, compared to its average volume of 223,539. DBV Technologies S.A. has a 12 month low of $2.92 and a 12 month high of $26.18. The stock has a market cap of $914.04 million, a price-to-earnings ratio of -4.40 and a beta of -1.10. The business has a 50-day simple moving average of $15.23 and a 200-day simple moving average of $11.72.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. New York State Common Retirement Fund purchased a new stake in DBV Technologies in the third quarter worth about $34,000. Two Sigma Investments LP bought a new stake in shares of DBV Technologies in the 3rd quarter worth approximately $167,000. Citadel Advisors LLC bought a new stake in shares of DBV Technologies in the 3rd quarter worth approximately $220,000. DLD Asset Management LP purchased a new stake in shares of DBV Technologies in the 3rd quarter worth approximately $250,000. Finally, Nan Fung Trinity HK Ltd. bought a new position in DBV Technologies during the 2nd quarter valued at approximately $340,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

Key DBV Technologies News

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: DBV reported a Phase III win in peanut allergy — a major clinical validation that materially de-risks the company’s lead program and supports future commercial potential. Vitesse finesse pays off: DBV wins in peanut allergy phase III
• Positive Sentiment: HC Wainwright materially raised EPS forecasts for FY2027–FY2029 (notably FY2029 to +$2.25), signaling stronger expected profitability and helping re-rate DBV’s outlook. This analyst revision is a key driver behind buying interest. HC Wainwright Expects Stronger Earnings for DBV Technologies
• Positive Sentiment: Broader broker reaction has been favorable: DBV was given an average “Moderate Buy” and firms (including Citizens JMP) published bullish commentary and price targets, which helped push the stock to a 1?year high. Those external endorsements amplify the impact of the trial and estimate upgrades. DBV Technologies S.A. (NASDAQ:DBVT) Given Average Recommendation of “Moderate Buy” by Brokerages Citizens Jmp Forecasts Strong Price Appreciation for DBV Technologies (NASDAQ:DBVT) Stock DBV Technologies (NASDAQ:DBVT) Hits New 1-Year High Following Analyst Upgrade
• Neutral Sentiment: Consensus still shows a deeply negative current-year EPS (around -$7.05), so near-term earnings remain weak; the market reaction reflects re?rating toward future upside rather than immediate profitability.
• Negative Sentiment: Lifesci Capital trimmed FY2026 EPS estimates (to about -$1.95), a reminder that some analysts remain cautious on near-term cash flow and runway — this is a modest headwind compared with the more prominent positive news.

Analysts Set New Price Targets

A number of analysts recently commented on DBVT shares. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research note on Wednesday. Zacks Research upgraded shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Friday, November 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, December 8th. Finally, Citizens Jmp increased their price target on shares of DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, DBV Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $35.38.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.